[{"orgOrder":0,"company":"St. Jude Children","sponsor":"Medicines for Malaria Venture | Eisai Inc | GHIT Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"SJ733","moa":"PfATP4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ Medicines for Malaria Venture | Eisai Inc | GHIT Fund","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children \/ Medicines for Malaria Venture | Eisai Inc | GHIT Fund"},{"orgOrder":0,"company":"Eisai","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"SJ733","moa":"PfATP4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eisai","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ GHIT Fund","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ GHIT Fund"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"||SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"R. Kiplin Guy","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SJ733","moa":"PfATP4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ R. Kiplin Guy","highestDevelopmentStatusID":"8","companyTruncated":"Eisai Inc \/ R. Kiplin Guy"}]

Find Clinical Drug Pipeline Developments & Deals for SJ733

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Neuroscience
                          Not Confirmed
                          Neuroscience
                          Not Confirmed

                          Details : Arakoda (tafenoquine succinate) is the inhibitor of hematin polymerization which is being evaluated with SJ733 for the treatment of P.vivax malaria.

                          Product Name : Arakoda

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 12, 2024

                          Lead Product(s) : Tafenoquine Succinate,SJ733

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Neuroscience
                          Not Confirmed
                          Neuroscience
                          Not Confirmed

                          Details : The financing will be used to develop a radical cure for P. vivax malaria. SJ000557733 (SJ733), an antimalarial drug candidate, has completed a Phase IIa trial for single administration and has shown efficacy and tolerability against P. vivax malaria.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          December 13, 2023

                          Lead Product(s) : SJ733

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : GHIT Fund

                          Deal Size : $5.4 million

                          Deal Type : Financing

                          blank

                          03

                          Neuroscience
                          Not Confirmed
                          Neuroscience
                          Not Confirmed

                          Details : SJ733 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Malaria, Falciparum.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 14, 2021

                          Lead Product(s) : SJ733

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : R. Kiplin Guy

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Neuroscience
                          Not Confirmed
                          Neuroscience
                          Not Confirmed

                          Details : SJ733 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Malaria.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 22, 2016

                          Lead Product(s) : SJ733

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Medicines for Malaria Venture | Eisai Inc | GHIT Fund

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank